DOPA-sparing strategy in the treatment of young onset Parkinson’s disease

Context: Late onset Parkinson’s disease (LOPD) is a neurodegenerative disorder afflicting individuals of ages 60 and older. However, 5–10% of cases can begin earlier between the ages 20 to 40, and are classified as young onset Parkinson disease (YOPD). Aim: In turn, this study aims to observe the tr...

Full description

Bibliographic Details
Main Authors: Abdul Qayyum Rana, Mohamad Saleh, Muhammad Saad Yousuf, Wasim Mansoor, Syed Hussaini, Maniza Rahman, Zohair Iqbal
Format: Article
Language:English
Published: Thieme Medical and Scientific Publishers Pvt. Ltd. 2016-01-01
Series:Journal of Neurosciences in Rural Practice
Subjects:
Online Access:http://www.thieme-connect.de/DOI/DOI?10.4103/0976-3147.172155
id doaj-90251b6175a54b89b591f83d5fdc34ea
record_format Article
spelling doaj-90251b6175a54b89b591f83d5fdc34ea2021-02-02T04:40:04ZengThieme Medical and Scientific Publishers Pvt. Ltd.Journal of Neurosciences in Rural Practice0976-31470976-31552016-01-01701676910.4103/0976-3147.172155DOPA-sparing strategy in the treatment of young onset Parkinson’s diseaseAbdul Qayyum Rana0Mohamad Saleh1Muhammad Saad Yousuf2Wasim Mansoor3Syed Hussaini4Maniza Rahman5Zohair Iqbal6Parkinson’s Clinic of Eastern Toronto and Movement Disorders Center, Toronto, CanadaParkinson’s Clinic of Eastern Toronto and Movement Disorders Center, Toronto, CanadaParkinson’s Clinic of Eastern Toronto and Movement Disorders Center, Toronto, CanadaParkinson’s Clinic of Eastern Toronto and Movement Disorders Center, Toronto, CanadaParkinson’s Clinic of Eastern Toronto and Movement Disorders Center, Toronto, CanadaParkinson’s Clinic of Eastern Toronto and Movement Disorders Center, Toronto, CanadaParkinson’s Clinic of Eastern Toronto and Movement Disorders Center, Toronto, CanadaContext: Late onset Parkinson’s disease (LOPD) is a neurodegenerative disorder afflicting individuals of ages 60 and older. However, 5–10% of cases can begin earlier between the ages 20 to 40, and are classified as young onset Parkinson disease (YOPD). Aim: In turn, this study aims to observe the trend in the choice of drug administered to patients with both YOPD and LOPD, with particular emphasis on this trend in its relation to the practice background of the neurologist. Settings and Design: A cross-sectional study was conducted in a community based Parkinson’s disease and movement disorder clinic. Statistical Analysis Used: Using a retrospective chart review data was obtained and analysed. Results: The results showed that 83% of general neurologists prescribed levodopa to their patients with YOPD, whereas movement-disorder specialists took a different approach altogether. They opted not to use levodopa and, in its stead, prescribed a mixture of alternate drugs.http://www.thieme-connect.de/DOI/DOI?10.4103/0976-3147.172155dopa-sparinggeneral neurologistlate-onset parkinson’s diseaselevodopamovement disorder specialistparkinson’s diseaseyoung onset parkinson’s disease
collection DOAJ
language English
format Article
sources DOAJ
author Abdul Qayyum Rana
Mohamad Saleh
Muhammad Saad Yousuf
Wasim Mansoor
Syed Hussaini
Maniza Rahman
Zohair Iqbal
spellingShingle Abdul Qayyum Rana
Mohamad Saleh
Muhammad Saad Yousuf
Wasim Mansoor
Syed Hussaini
Maniza Rahman
Zohair Iqbal
DOPA-sparing strategy in the treatment of young onset Parkinson’s disease
Journal of Neurosciences in Rural Practice
dopa-sparing
general neurologist
late-onset parkinson’s disease
levodopa
movement disorder specialist
parkinson’s disease
young onset parkinson’s disease
author_facet Abdul Qayyum Rana
Mohamad Saleh
Muhammad Saad Yousuf
Wasim Mansoor
Syed Hussaini
Maniza Rahman
Zohair Iqbal
author_sort Abdul Qayyum Rana
title DOPA-sparing strategy in the treatment of young onset Parkinson’s disease
title_short DOPA-sparing strategy in the treatment of young onset Parkinson’s disease
title_full DOPA-sparing strategy in the treatment of young onset Parkinson’s disease
title_fullStr DOPA-sparing strategy in the treatment of young onset Parkinson’s disease
title_full_unstemmed DOPA-sparing strategy in the treatment of young onset Parkinson’s disease
title_sort dopa-sparing strategy in the treatment of young onset parkinson’s disease
publisher Thieme Medical and Scientific Publishers Pvt. Ltd.
series Journal of Neurosciences in Rural Practice
issn 0976-3147
0976-3155
publishDate 2016-01-01
description Context: Late onset Parkinson’s disease (LOPD) is a neurodegenerative disorder afflicting individuals of ages 60 and older. However, 5–10% of cases can begin earlier between the ages 20 to 40, and are classified as young onset Parkinson disease (YOPD). Aim: In turn, this study aims to observe the trend in the choice of drug administered to patients with both YOPD and LOPD, with particular emphasis on this trend in its relation to the practice background of the neurologist. Settings and Design: A cross-sectional study was conducted in a community based Parkinson’s disease and movement disorder clinic. Statistical Analysis Used: Using a retrospective chart review data was obtained and analysed. Results: The results showed that 83% of general neurologists prescribed levodopa to their patients with YOPD, whereas movement-disorder specialists took a different approach altogether. They opted not to use levodopa and, in its stead, prescribed a mixture of alternate drugs.
topic dopa-sparing
general neurologist
late-onset parkinson’s disease
levodopa
movement disorder specialist
parkinson’s disease
young onset parkinson’s disease
url http://www.thieme-connect.de/DOI/DOI?10.4103/0976-3147.172155
work_keys_str_mv AT abdulqayyumrana dopasparingstrategyinthetreatmentofyoungonsetparkinsonsdisease
AT mohamadsaleh dopasparingstrategyinthetreatmentofyoungonsetparkinsonsdisease
AT muhammadsaadyousuf dopasparingstrategyinthetreatmentofyoungonsetparkinsonsdisease
AT wasimmansoor dopasparingstrategyinthetreatmentofyoungonsetparkinsonsdisease
AT syedhussaini dopasparingstrategyinthetreatmentofyoungonsetparkinsonsdisease
AT manizarahman dopasparingstrategyinthetreatmentofyoungonsetparkinsonsdisease
AT zohairiqbal dopasparingstrategyinthetreatmentofyoungonsetparkinsonsdisease
_version_ 1724305391405236224